Tech Company Financing Transactions
Agomab Funding Round
On 7/13/2022, Agomab secured $40.5 million in Series B funding from Pfizer Venture Investments, Asabys Partners and private investors.
Transaction Overview
Company Name
Announced On
7/13/2022
Transaction Type
Venture Equity
Amount
$40,500,000
Round
Series B
Investors
Proceeds Purpose
The combined capital will be used to support the clinical evaluation of Agomab's product candidates and to further expand the company's pipeline and organization.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Franklin Rooseveltlaan 348
Ghent, 9000
Belgium
Ghent, 9000
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tim Knotnerus
Chief Financial Officer
Tolga Hassan
Chief Medical Officer
Philippe Wiesel
Chief Scientific Officer
Paolo Michieli
VP - Bus. Development
Torsten Dreier
VP - Bus. Development
Paul van der Horst
VP - General Counsel
Ellen Lefever
VP - R & D
Ramon Bosser
VP - R & D
Reginald Brys
Browse more venture capital transactions:
Prev: 7/13/2022: Helios Project venture capital transaction
Next: 7/13/2022: Deci venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs